-
AKTIS ONCOLOGY APPOINTS KYLE KUVALANKA CHIEF FINANCIAL OFFICER
05 Nov 2025 12:36 GMT
… Strategy and Alliance Management at Millennium Pharmaceuticals, the Takeda Oncology Company, and … Vice President, Investor Relations at Millennium Pharmaceuticals. Mr. Kuvalanka holds an MBA …
-
Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
31 Oct 2025 02:15 GMT
… neuroblastoma companies including GE Healthcare, Millennium Pharmaceuticals, Genentech, Actuate Therapeutics, among others …
-
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
28 Oct 2025 12:51 GMT
… in the U.S. by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary …
-
Pevonedistat hydrochloride by Millennium Pharmaceuticals for Essential Thrombocythemia: Likelihood of Approval
27 Oct 2023 16:35 GMT
… the below form
By GlobalData
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals (Takeda Oncology), a subsidiary …
-
Ixazomib citrate by Millennium Pharmaceuticals for Lymphoblastic Lymphoma: Likelihood of Approval
27 Oct 2023 16:35 GMT
… and graft versus host disease.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals (Takeda Oncology), a subsidiary …
-
Pevonedistat hydrochloride by Millennium Pharmaceuticals for Solid Tumor: Likelihood of Approval
10 Feb 2023 09:11 GMT
… is under clinical development by Millennium Pharmaceuticals and currently in Phase I … refractory acute lymphocytic leukemia.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals is a biopharmaceutical company that …
-
Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight
07 Oct 2025 00:54 GMT
… Tianqing Pharmaceutical Group Co., Ltd., Millennium Pharmaceuticals, Inc., Takeda, Synthekine, Hangzhou Sumgen …
-
Immune Thrombocytopenic Purpura Market to Grow at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight
15 Sep 2025 17:00 GMT
… .4
TAK-079 (mezagitamab): Takeda (Millennium Pharmaceuticals)
11.5
PF-06835375: Pfizer … , GC Pharma, UCB Biopharma, Takeda (Millennium Pharmaceuticals), Pfizer, Genosco and Oscotec, Vertex …
-
In ‘biotech winter,’ Boston startups, jobs, and science are being swept away
15 Sep 2025 10:15 GMT
… Dunsire, the former CEO of Millennium Pharmaceuticals who has spent more than …
-
Anaplastic Thyroid Cancer - Pipeline Insight Report 2018 Featuring Exelixis, Eisai, AstraZene, CaIgnyta, Millennium Pharmaceuticals & Novartis - ResearchAndMarkets.com
22 Feb 2018 20:05 GMT
…
Exelixis
Eisai
AstraZene
CaIgnyta Inc.
Millennium Pharmaceuticals Inc.
Novartis
For more information …
About
© 1995-2025